\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes Research Infrastructures HealthTechnical problems with the submission system continue to exsist for the topics
HORIZON-HLTH-2021-CORONA-01-01 Vaccines & therapeutic clinical trials to boost COVID-19 prevention and treatment
HORIZON-HLTH-2021-CORONA-01-02 Cohorts united against COVID-19 variants of concern
HORIZON-INFRA-EMERGENCY-2021-01 FAIR and open data sharing in support to European preparedness for COVID-19 and other infectious diseases
HORIZON-INFRA-EMERGENCY-2021-02 Research infrastructure services for rapid research responses to COVID-19 and other infectious disease epidemics
For this reason, the deadline for submission is postponed from 11 May (as was previously communicated) to 20 May at 17:00.
Source: Funding and Tender Portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
